Ocular Therapeutix, INC: directors' dealings · United States · SEC (Form 4)

About Ocular Therapeutix, INC

Ocular Therapeutix, Inc. is a United States-based biopharmaceutical company listed on the NASDAQ, with a core focus on ophthalmology and, in particular, retinal disease. The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts. Its strategy is built around a proprietary bioresorbable hydrogel platform designed to deliver therapeutic agents locally and in a programmed manner within the eye. That platform approach is important competitively: in eye care, longer durability, better adherence, and fewer repeat procedures can be clinically meaningful and commercially attractive, especially in retinal diseases where treatment burden is a major issue.([sec.gov](https://www.sec.gov/Archives/edgar/data/1393434/000110465924054052/tm248018d2_ars.pdf)) Ocular’s commercial anchor is DEXTENZA, an intracanalicular dexamethasone insert used in the United States for the treatment of post-surgical ocular inflammation and pain, as well as ocular itching associated with allergic conjunctivitis. Current revenue is largely generated through DEXTENZA sales to specialty distributors and through direct sales to certain ambulatory surgery centers and physicians’ offices. While this commercial base is still relatively small compared with large ophthalmology franchises, it gives the company an approved product, operating experience in the U.S. market, and a revenue stream that supports ongoing development efforts.([sec.gov](https://www.sec.gov/Archives/edgar/data/1393434/000110465924054052/tm248018d2_ars.pdf)) The key value driver is AXPAXLI, also known as OTX-TKI, Ocular’s intravitreal axitinib implant for retinal disorders, with wet age-related macular degeneration (wet AMD) as the lead indication. In 2026, the company reported that the SOL-1 Phase 3 trial had delivered superiority results with materially fewer rescue treatments than single-dose aflibercept, and management said it was preparing for an NDA submission subject to ongoing discussions with the U.S. FDA. Ocular also stated that SOL-R continues to progress, with topline data expected in the first quarter of 2027. Beyond these late-stage programs, the company maintains additional development assets at earlier stages, underscoring a broader pipeline strategy rather than reliance on a single asset.([sec.gov](https://www.sec.gov/Archives/edgar/data/1393434/000110465926055241/tm2613442d1_ex99-1.htm)) Geographically, Ocular’s commercial activity remains primarily U.S.-focused, although it has licensing arrangements covering parts of Asia through AffaMed Therapeutics for selected products. The company’s Bedford site includes manufacturing, laboratory, warehouse and office space, and it has disclosed a future corporate headquarters on the same campus. From a financial standpoint, Ocular is still a development-heavy biotech, but it strengthened its balance sheet through a sizable 2025 equity raise. Recent milestones include positive late-stage clinical execution, continued advancement of its retina franchise, and preparations for a potential future commercial launch of AXPAXLI if regulatory discussions progress favorably.([sec.gov](https://www.sec.gov/Archives/edgar/data/1393434/000110465926010664/ocul-20251231x10k.htm))